An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Public ClinicalTrials.gov record NCT02531516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) based on conventional imaging assessed by blinded independent central review (BICR).
Study identification
- NCT ID
- NCT02531516
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,503 participants
Conditions and interventions
Conditions
Interventions
- Apalutamide Drug
- Bicalutamide Drug
- Bicalutamide Placebo Drug
- Apalutamide Placebo Drug
- GnRH (agonist) Drug
- 74-80 Grays (units of radiation) Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2015 (Actual)
- Primary completion
- Mar 1, 2027 (Estimated)
- Completion
- Dec 29, 2028 (Estimated)
- Last update posted
- Nov 3, 2026
2015 – 2028
United States locations
- U.S. sites
- 60
- U.S. states
- 28
- U.S. cities
- 60
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Homewood | Alabama | — | — |
| Not listed | Chandler | Arizona | — | — |
| Not listed | Scottsdale | Arizona | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Bakersfield | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | San Bernardino | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Middlebury | Connecticut | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Daytona Beach | Florida | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Hialeah | Florida | — | — |
| Not listed | Lakewood Rch | Florida | — | — |
| Not listed | Naples | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Meridian | Idaho | — | — |
| Not listed | Evergreen Park | Illinois | — | — |
| Not listed | Harvey | Illinois | — | — |
| Not listed | Jeffersonville | Indiana | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Ashland | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Scarborough | Maine | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Morristown | New Jersey | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Poughkeepsie | New York | — | — |
| Not listed | Rochester | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Cary | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Springfield | Oregon | — | — |
| Not listed | Bala-Cynwyd | Pennsylvania | — | — |
| Not listed | Bryn Mawr | Pennsylvania | — | — |
| Not listed | Lancaster | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | East Greenwich | Rhode Island | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Myrtle Beach | South Carolina | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Fairfax | Virginia | — | — |
| Not listed | Virginia Beach | Virginia | — | — |
| Not listed | Burien | Washington | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 203 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02531516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2026 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02531516 live on ClinicalTrials.gov.